Differentiation-promoted pluripotent stem cell and use thereof

Patent metadata

Field	Value
Publication number	US-2020299643-A1
Application number	US-201716086206-A
Country	US
Kind code	A1
Filing date	Mar 27, 2017
Priority date	Mar 31, 2016
Publication date	Sep 24, 2020
Grant date	—

Abstract

A culture medium for inducing a pluripotent stem cell into a differentiation-promoted pluripotent stem cell, the medium including a Glycogen synthase kinase 3β (GSK3β) inhibitor, a Bone morphogenic protein (BMP) signaling inhibitor, and a Transforming growth factor (TGF)-β inhibitor as active ingredients.

First claim

1 . A culture medium for inducing a pluripotent stem cell into a differentiation-promoted pluripotent stem cell, the medium comprising, as active ingredients:
a Glycogen synthase kinase 3β (GSK3β) inhibitor; a Bone morphogenic protein (BMP) signaling inhibitor; and a Transforming growth factor (TGF)-β inhibitor.

2 . A method for manufacturing a differentiation-promoted pluripotent stem cell, comprising:
culturing a pluripotent stem cell in the culture medium according to claim 1 .

3 . The method for manufacturing a differentiation-promoted pluripotent stem cell according to claim 2 ,
wherein the pluripotent stem cell is not selected in advance according to origin, or a level of differentiation potential into endoderm, mesoderm, or ectoderm.

4 . A differentiation-promoted pluripotent stem cell,
wherein expression levels of endoderm, mesoderm, and ectoderm markers are increased compared with a control cell.

5 . The differentiation-promoted pluripotent stem cell according to claim 4 , which is manufactured by the method for manufacturing according to claim 2 .

6 . A differentiation-promoted pluripotent stem cell,
wherein a level of differentiation potential into endoderm, mesoderm, and ectoderm is improved compared with a control cell.

7 . The differentiation-promoted pluripotent stem cell according to claim 6 , which is manufactured by the method for manufacturing according to claim 2 .

8 . A method for manufacturing a neural stem cell mass, comprising:
culturing the differentiation-promoted pluripotent stem cell according to claim 4 in a culture medium containing a GSK3β inhibitor, a TGF-β inhibitor, a Rho-associated protein kinase (ROCK) inhibitor, a Fibroblast Growth Factor 2 (FGF2), and a Leukemia Inhibitory Factor (LIF) as active ingredients.

9 . A neural stem cell mass,
wherein almost all neural stem cells constituting the neural stem cell mass do not substantially express an endoderm marker and a mesoderm marker.

10 . The neural stem cell mass according to claim 9 , which is manufactured by the method for manufacturing according to claim 8 .

11 . A method for manufacturing endoderm or tissue derived from the endoderm, comprising:
differentiating the differentiation-promoted pluripotent stem cell according to claim 4 .

12 . A method for manufacturing mesoderm or tissue derived from the mesoderm, comprising:
differentiating the differentiation-promoted pluripotent stem cell according to claim 4 .

13 . A method for manufacturing ectoderm or tissue derived from the ectoderm, comprising:
differentiating the differentiation-promoted pluripotent stem cell according to claim 4 .

Assignees

• Univ Keio

Inventors

• Okano Hideyuki
• Akamatsu Wado
• FUJIMORI Koki
• Matsumoto Takuya
• KUZUMAKI Naoko
• Kisa Fumihiko

Classifications

• C12N5/0623 Primary

  Stem cells · CPC title

• C12N5/10

  Cells modified by introduction of foreign genetic material · CPC title

• C12N2506/45

  from artificially induced pluripotent stem cells · CPC title

• C12N2501/155

  Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title

• C12N2501/235

  Leukemia inhibitory factor [LIF] · CPC title